DR6.F ACADIA Pharmaceuticals Inc

Healthcare Biotechnology Frankfurt Exchange
16.24 EUR
Close of Nov 11, 2026
14.62 25.98
Market cap
EUR 2.81B
P/E
10.7x
P/B
2.19x
ROE
8.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DR6.F undervalued?

Graham number
Price16.24
Graham value15.93
Premium2.0%

DR6.F trades 2.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ACADIA Pharmaceuticals Inc fundamental analysis

No fundamental analysis for ACADIA Pharmaceuticals Inc yet.

ACADIA Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the sy…

Full company profile